Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity

@article{Jones2008UtilityOD,
  title={Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity},
  author={Robin L. Jones},
  journal={Expert Review of Cardiovascular Therapy},
  year={2008},
  volume={6},
  pages={1311 - 1317}
}
  • Robin L. Jones
  • Published 1 November 2008
  • Medicine, Chemistry
  • Expert Review of Cardiovascular Therapy
Dexrazoxane is a derivative of the powerful metal-chelating agent ethyl enediamine tetra acetic acid. Its cardioprotective effect is thought to be due to its ability to chelate iron and reduce the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. Preclinical studies have confirmed that dexrazoxane has significant activity as a cardioprotective agent against anthracycline-induced cardiotoxicity. Dexrazoxane is well-tolerated, with… 
Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.
TLDR
It is concluded that dexrazoxane can be safely combined with epirubicin and that pre-treatment with dexraz Roxoxane attenuates epirUBicin-induced generation of reactive oxygen species and subsequent genotoxicity and apoptosis, which can be effectively mitigated by using dexrazxane.
Activity of Dexrazoxane and Amifostine Against Late Cardiotoxicity Induced by the Combination of Doxorubicin and Cyclophosphamide In Vivo
TLDR
Results revealed that the cardiotoxicity of DC combination displays specific morphological hallmark and evolution in time, different to those described after doxorubicin single treatment.
Prevention and Treatment of Doxorubicin-Induced Cardiotoxicity by Dexrazoxane and Schisandrin B in Rabbits
TLDR
Schisandrin B had dose-dependent effects in decreasing the magnitude of doxorubicin-induced indicators of cardiomyopathy to a degree that approximated the decrease produced by dexrazoxane treatment.
Modulatory Effects of Dexrazoxane Against Genotoxicity and Lipid Peroxidation Induced by Idarubicin in HepG2 Cells
Background: Idarubicin is an anthracycline antibiotic drug widely used in chemotherapy. Dexrazoxane is an iron chelator used clinically against anthracyclines-induced cardiotoxicity. The present
Protective Effects of Apocynum venetum Against Pirarubicin-Induced Cardiotoxicity.
TLDR
The study suggests the anti-oxidant and anti-apoptotic properties of AVLE may be responsible for the observed cardioprotective effects of Pirarubicin.
Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice
TLDR
Evidence is provided that dexrazoxane has a protective role in the abatement of doxorubicin-induced aneuploidy, and this activity resides, at least in part, in its radical scavenger activity.
Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs
TLDR
Current evidence supports the utility of cardioprotective modalities as adjunct treatment prior to and during anthracycline chemotherapy, including dexrazoxane, early hypertension management, and dietary supplementation of nitrate with beetroot juice or other medicinal botanical derivatives, which have both antihypertensive and anti-AIC properties.
Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer
TLDR
Nebivolol treatment prevented the occurrence of anthracyclines-induced cardiomyopathy in the short term and the benefit of new echocardiographic imaging methods such as TDI and STI in the screening of early cardiac dysfunction induced by cytostatic treatment is shown.
Management of Cardiac Toxicity Induced by Chemotherapy
TLDR
This present review aimed to provide a perspective and an update of the current pharmacotherapy approaches for the prevention and management of cardiotoxicity from antiblastic chemotherapy, by navigating the current knowledge and clinical indications in support of the medical interventions.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
TLDR
Preliminary results indicate that dexrazoxane reduces cardiac toxicity in children and adolescents receiving anthracycline-based therapy for a range of malignancies and permits the administration of doxorubicin beyond standard cumulative doses; however, it is unclear whether this will translate into prolonged survival.
Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
The bisdioxopiperazine dexrazoxane (ICRF-187) has proven to be clinically very effective in reducing the cardiotoxicity of doxorubicin and other anthracyclines. Doxorubicin is thought to exert its
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
TLDR
A pharmacoeconomic evaluation of the ability of dexrazoxane to prevent cardiac-related adverse events in patients with Stage IIIB or IV metastatic breast cancer and the results may broaden the range of therapeutic possibilities for anthracyclines in adjuvant and metastatic therapy of breast cancer.
Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo
TLDR
The results of this first in vivo study suggest that the role of iron and its chelation in anthracycline cardiotoxicity is not as trivial as originally believed and/or other mechanisms unrelated to iron-catalyzed ROS production are involved.
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
TLDR
ICRF187 seems to have provided highly effective cardioprotection to this small group of children with end-stage malignancy, and severe cardiotoxicity was seen in a similar group treated with comparable anthracycline doses but without ICRF187.
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.
BACKGROUND Anthracycline-induced cardiotoxicity has led to the adoption of empirical dose limits that may restrict continued use of anthracyclines among patients who might benefit. Dexrazoxane, a
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
  • M. Venturini, A. Michelotti, R. Rosso
  • Medicine, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
The clinical use of dexrazoxane should be recommended in patients whose risk of developing cardiotoxicity could hamper the eventual use and possible benefit of epirubicin, and who have previously received adjuvant chemotherapy that contained anthracyclines.
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
TLDR
The evidence supports the use of dexrazoxane to provide protection against the cardiotoxicity associated with conventional-dose doxorubicin in patients with advanced but Anthracycline-sensitive cancer, in whom the continued use of anthracyCline-containing chemotherapy is indicated in the opinion of the treating physician.
Cardioprotective interventions for cancer patients receiving anthracyclines.
TLDR
It is concluded that if the risk of cardiac damage is expected to be high, it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines, but for each individual patient clinicians should weigh the cardioprotective effect of dexrazxane against the possible risk of adverse effects.
Anthracycline cardiotoxicity
TLDR
With the growing number of paediatric malignancy survivors and the increasing use of anthracyclines in the adjuvant treatment of breast cancer, the cardiotoxicity associated with these agents will remain a formidable issue for physicians.
...
1
2
3
4
5
...